Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Rezolute, Inc.RZLT · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required |
| Reliability | 0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| Peer failure rate | 1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $12.5M to $120M assetstotal assets $112.8M[1] |
| Warnings | short runway, thin data · fortress balance sheetnot computable: degenerate inputs |
| Inputs computable | 6 of 14 |
| Graded from | filings received through Sep 24, 202615 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $4.632026-10-08; market equity $448.3M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Sep 24, 2026; the document on sec.gov.
Rezolute, Inc. (“Rezolute”, the “Company”, “we” or “us”) is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (“HI”). Our lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 44.2 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | (9.0%) | [1,5-7] | (6.6%) | 44.2 | 811 | 2026-06-30 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 43.1 | |||||||
| Twelve-month failure probability | 0.11% | 0.07% | 60.3 | 248 | 2026-06-30 | ||
| Altman Z double-prime | (4.40) | [1,8-13] | (0.31) | 51.7 | 756 | 2026-06-30 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| EBITDA must exceed $100,000 | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| latest aligned inputs end 2021-06-30; latest annual assets end 2026-06-30 | |||||||
| Current ratio | 9.68x | [8-9] | 2.96x | 17.4 | 839 | 2026-06-30 | |
| Growth and financing, sleeve percentile 53.2 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| four annual observations are required; found 0 | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| four consecutive annual FCF observations are required; found 3 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| one or more required annual facts are missing | |||||||
| Asset growth, three years | (3.0%) | [1,7,14-15] | 2.1% | 58.9 | 704 | 2026-06-30 | |
| Net share issuance, one year | 6.5% | [16-17] | 2.5% | 47.6 | 634 | 2026-09-21 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (50.1%) | 8.0% | 14 | hotter than 14 of 100 peers |
| Distance from 52-week high | (57.6%) | (31.4%) | 19 | closer to its high than 19 of 100 peers |
| EBIT to enterprise value | (18.3%) | (1.5%) | 24 | pricier than 76 of 100 peers |
| Free cash flow yield | (9.9%) | (1.0%) | 31 | pricier than 69 of 100 peers |
| Book value to price | 0.22 | 0.28 | 44 | pricier than 56 of 100 peers |
| Sales to price | not computable | 0.31 | required accounting or market input is missing | |
| Composite equity issuance, five years | 241.8% | 20.3% | 93 | more equity-funded than 93 of 100 peers |
| Relative strength against the sector, log excess return | (0.91) | (0.14) | 14 | ahead of 14 of 100 peers |
Inputs: market equity $448.8M; EBIT -$83.0M; free cash flow -$44.6M; book equity $100.7M; debt $14.3M; cash $10.6M[16].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2026-06-30 | ||
|---|---|---|
| Return on assets above zero | (44.2%) | ✗ fail[5,7] |
| Operating cash flow above zero | -$64.6M | ✗ fail[6] |
| Return on assets improved | 11.8 pts | ✓ pass[5,7,14,18] |
| Operating cash flow exceeds net income | $13.0M | ✓ pass[5-6] |
| Long-term leverage fell | n/a[1,7,14] | |
| Current ratio improved | (468.9 pts) | ✗ fail[8-9,19-20] |
| No new shares issued | 6.5% | ✗ fail[16-17] |
| Gross margin improved | n/a | |
| Asset turnover improved | n/a[7,14] | |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $112.8M | 2026-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 2 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $10.6M | 2026-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $41.0M | 2021-06-30 | 2022-09-15 | 10-K | filing · viewer · series |
| 4 | total debt | us-gaap:LongTermDebt | $14.0M | 2021-06-30 | 2022-09-15 | 10-K | filing · viewer · series |
| 5 | net income | us-gaap:NetIncomeLoss | -$77.6M | 2026-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 6 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$64.6M | 2026-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 7 | assets | us-gaap:Assets | $175.5M | 2025-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 8 | current assets | us-gaap:AssetsCurrent | $110.5M | 2026-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 9 | current liabilities | us-gaap:LiabilitiesCurrent | $11.4M | 2026-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 10 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$481.4M | 2026-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$83.0M | 2026-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 12 | book equity | us-gaap:StockholdersEquity | $100.7M | 2026-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 13 | liabilities | us-gaap:Liabilities | $12.2M | 2026-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 14 | assets | us-gaap:Assets | $132.7M | 2024-06-30 | 2025-09-17 | 10-K | filing · viewer · series |
| 15 | assets | us-gaap:Assets | $123.7M | 2023-06-30 | 2024-09-19 | 10-K | filing · viewer · series |
| 16 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 96,722,333 | 2026-09-21 | 2026-09-24 | 10-K | filing · viewer · series |
| 17 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 90,811,368 | 2025-09-15 | 2025-09-17 | 10-K | filing · viewer · series |
| 18 | net income | us-gaap:NetIncomeLoss | -$74.4M | 2025-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 19 | current assets | us-gaap:AssetsCurrent | $171.1M | 2025-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 20 | current liabilities | us-gaap:LiabilitiesCurrent | $11.9M | 2025-06-30 | 2026-09-24 | 10-K | filing · viewer · series |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$51.5M | 2026-03-31 | 2026-05-12 | 10-Q | filing · viewer · series |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$37.8M | 2025-12-31 | 2026-02-12 | 10-Q | filing · viewer · series |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$17.4M | 2025-09-30 | 2025-11-06 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.